Novartis gene therapy is cost effective at up to $900,000 -U.S. group
February 22, 2019 at 13:39 PM EST
An experimental gene therapy for spinal muscular atrophy (SMA)developed by Swiss drugmaker Novartis AG would offer value at a price of $310,000 to $900,000, according an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments.
